0001470831-25-000435.txt : 20251218 0001470831-25-000435.hdr.sgml : 20251218 20251218142106 ACCESSION NUMBER: 0001470831-25-000435 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251218 DATE AS OF CHANGE: 20251218 EFFECTIVENESS DATE: 20251218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KAZIA THERAPEUTICS LTD CENTRAL INDEX KEY: 0001075880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-567348 FILM NUMBER: 251582621 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW PROVINCE COUNTRY: C3 ZIP: 2000 BUSINESS PHONE: 01161298780088 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW PROVINCE COUNTRY: C3 ZIP: 2000 FORMER COMPANY: FORMER CONFORMED NAME: NOVOGEN LTD DATE OF NAME CHANGE: 19981228 D 1 primary_doc.xml X0708 D LIVE 0001075880 KAZIA THERAPEUTICS LTD THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 AUSTRALIA 2000 01161298780088 AUSTRALIA NOVOGEN LTD Corporation true John Friend Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Bryce Carmine Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Steven Coffey Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Ebru Davidson Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Robert Apple Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Jeffrey Bonacorda Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Elissa Hansen Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Biotechnology Decline to Disclose 06b false 2025-12-03 false true true true false 0 T.R. Winston & Company LLC 10571 Konik Capital Partners LLC None 7 World Trade Center 46th Floor New York NY NEW YORK 10007 AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE FL FLORIDA GA GEORGIA ID IDAHO IL ILLINOIS IN INDIANA KS KANSAS KY KENTUCKY LA LOUISIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MT MONTANA NV NEVADA NJ NEW JERSEY NY NEW YORK OH OHIO OR OREGON PA PENNSYLVANIA PR PUERTO RICO SD SOUTH DAKOTA TN TENNESSEE TX TEXAS UT UTAH WA WASHINGTON WY WYOMING true 55251088 55251088 0 Includes pre-funded warrants for 938,490 ADSs, each representing 500 ordinary shares, and their aggregate exercise price at $0.0001 per ADS; and aggregate exercise price of warrants to placement agent for 700,013 ADSs at exercise price $7.5 per ADS. false 65 3328063 0 The amount reflects placement agent fee of up to 7% of the gross proceeds. In addition, placement agent also received warrants to purchase up to 700,013 ADSs at an exercise price of $7.50 per ADSs. 0 false KAZIA THERAPEUTICS LTD /s/ John Friend John Friend Chief Executive Officer 2025-12-18